Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0224

Investigator meeting · Dr. Valentina Xu

08 Mar 2026 · In person · Dr. Valentina Xu, Royal Marsden · MSL Luis Ortega · Lumeva

ReviewedManualENG-0224—

Capture insight from this engagement

Location: Royal Marsden
Therapeutic area: Neurology
Country: United Kingdom
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Dosing in hepatic impairment
Chronic migraine data
Drug interactions

Scientific content used

Chronic migraine scientific platform

Questions raised

What is the persistence rate at 18 months in real-world cohorts?
Any data in patients with medication-overuse headache?

Notes

Investigator meeting with headache specialist at Royal Marsden. Discussed dosing in hepatic impairment, chronic migraine data, drug interactions.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Schedule follow-up in 6 weeks

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 2
Depth of exchange: 1
Actionability: 1

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0224

Audit history (0)

All create, update and approval events for this record

No audit events in sample data